Joan Butterton, Merck Research Laboratories VP of global clinical development, infectious diseases (Merck)
Merck's experimental HIV drug islatravir hits with a PhIII combo win and FDA filing plans
Back in March, Merck and Gilead agreed to a partnership to challenge GlaxoSmithKline on long-acting HIV meds — by combining one drug from both Merck …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
